Boston, MA 05/23/2013 (wallstreetpr) – The share prices of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) surged by 13.44 percent to close at $7.26 per share for the end of last trading session. The shares traded in the range of $6.45 to $7.30 per share during the day. The biopharmaceutical company is recently involved in the development of pain management system for post operative pains.
Sufentil Nano Tab PCA system reaches primary end point
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) had reported to have achieved the primary endpoint in its research to develop the Sufentil Nano Tab PCA system aimed at management of post operative pains. Results of the research reiterated that the patients who received the sufentil Nano Tab PCA system were able to report greater Summed Pain Intensity Difference 48 (SPID 48) compared to the placebo treated patients.
The biopharmaceutical company based in United States is primarily engaged in the development and commercialization of treatment therapies for acute and breakthrough pains. Another product candidate of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) includes Sufentanil Nano Tab BTP Management system for relieving cancer patients who suffer from breakthrough pains. The company had also developed pain relief treatment for patients especially on the battlefield or civilian trauma or injury, which provides for non invasive, fast relief treatment of moderate to acute pains.
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) presently has 37.06 million shares outstanding and the institutional holding amounts to 79 percent of its ownership. The total market capitalization of the company is $269.05 million and the average trading volume is 363,111 share per day.
